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Late presentation (LP) for HIV care across Europe 
remains a significant issue. We provide a cross-Euro-
pean update from 34 countries on the prevalence and 
risk factors of LP for 2010–2013. People aged ≥ 16 pre-
senting for HIV care (earliest of HIV-diagnosis, first 
clinic visit or cohort enrolment) after 1 January 2010 
with available CD4 count within six months of pres-
entation were included. LP was defined as presenta-
tion with a CD4 count < 350/mm3 or an AIDS defining 
event (at any CD4), in the six months following HIV 
diagnosis. Logistic regression investigated changes in 
LP over time. A total of 30,454 people were included. 
The median CD4 count at presentation was 368/
mm3 (interquartile range (IQR) 193–555/mm3), with 
no change over time (p = 0.70). In 2010, 4,775/10,766 
(47.5%) were LP whereas in 2013, 1,642/3,375 (48.7%) 
were LP (p = 0.63). LP was most common in central 
Europe (4,791/9,625, 49.8%), followed by northern 
(5,704/11,692; 48.8%), southern (3,550/7,760; 45.8%) 
and eastern Europe (541/1,377; 38.3%; p < 0.0001). 
There was a significant increase in LP in male and 
female people who inject drugs (PWID) (adjusted odds 
ratio (aOR)/year later 1.16; 95% confidence interval 
(CI): 1.02–1.32), and a significant decline in LP in north-
ern Europe (aOR/year later 0.89; 95% CI: 0.85–0.94). 
Further improvements in effective HIV testing strate-
gies, with a focus on vulnerable groups, are required 
across the European continent.
Introduction
The United Nations Programme on HIV/AIDS (UNAIDS) 
recently released an ambitious strategy that calls for 
90% of HIV infections to be diagnosed by 2020 [1]. 
Many people however remain unaware of their HIV 
status and cascades for care for HIV vary widely from 
country to country within Europe, with 20–70% of peo-
ple infected with HIV remaining undiagnosed [2-4]. 
These estimates rely on estimates of the population 
with HIV, which itself is estimated using a variety of 
different methods [5]. In addition, ca 40–60% of HIV-
positive people are diagnosed with HIV at a late stage 
of infection [6,7], defined as people presenting for HIV 
care with a CD4 count of less than 350/mm3 or an AIDS 
defining illness [8]. Individuals at greatest risk of late 
diagnosis and/or late entry into care have poorer out-
comes and higher resource use once diagnosed. Those 
who are unware of their HIV status are also less likely 
to take steps to prevent onward transmission to others 
[9-11]. However, many who present late, do so because 
they perceive their risk for HIV as low, as they have few 
sex partners for example.
The rates of late presentation (LP) among newly diag-
nosed HIV positive people in any setting serves as a 
proxy of effective HIV testing strategies. Such strate-
gies should ensure people enter appropriate care to 
start antiretroviral therapy (ART) [12]. However, the 
extent to which these recommendations are imple-
mented across Europe is variable [13]. Following the 
recent publication of findings from the Strategic Timing 
of Antiretroviral Treatment (START) [14], treatment is 
now recommended for all people infected with HIV [13]. 
The World Health Organization (WHO) recognises early 
HIV diagnosis as a crucial first step in the successful 
care of HIV [15]. There are a number of programmes and 
initiatives to increase HIV testing; these include indica-
tor-condition-guided HIV testing and national HIV test-
ing strategies, linkage and retention in care of those 
already diagnosed. Furthermore, there are initiatives 
specifically aimed at reducing HIV transmission, such 
as harm-reduction, condom use, initiation of antiretro-
viral therapy and pre-exposure prophylaxis [16-18].
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The Collaboration of Observational HIV Epidemiological 
Research Europe (COHERE) study provides a unique 
opportunity to describe the epidemiology of those 
diagnosed HIV-positive at a late stage of HIV infection 
compared with those diagnosed earlier, and to look at 
geographical differences within HIV exposure groups. 
COHERE is a collaboration of 39 cohorts across Europe 
and is part of the EuroCoord network (www.EuroCoord.
net). COHERE was established in 2005 with the aim of 
conducting epidemiological research on the prognosis 
and outcome of HIV-positive people, which the indi-
vidual contributing cohorts cannot address themselves 
because of insufficient sample size or heterogeneity 
of specific subgroups of HIV-positive people. Local 
ethics committee and/or other regulatory approvals 
were obtained as applicable according to local and/or 
national regulations in all participating cohorts unless 
no such requirement applied to observational studies. 
Each cohort submits data using the standardised HIV 
Collaboration Data Exchange Protocol (HICDEP) [19], 
including information on patient demographics, use of 
combination antiretroviral therapy (cART), CD4 counts, 
AIDS, and deaths. Further details can be found on 
EuroCoord website [20].
Previous work showed an overall 4% decrease in LP 
per year of late presentation between 2000 and 2010 
across Europe, albeit with an increase over time in 
people who inject drugs (PWID) [7]. The aims of this 
update were to determine if the downward trend in 
LP observed between 2000 and 2010 continued, and 
whether there were any groups of individuals in which 
LP continues to increase.
Methods
Patients
Twenty-four cohorts including data from 34 European 
countries provided data for the present analysis. All 
people aged ≥ 16 years, who presented for care (defined 
as earliest date of HIV diagnosis, first clinic visit, or 
enrolment into the participating cohort, referred to 
as ‘baseline’) for the first time after 1 January 2010 
were included to provide an update to the report from 
2013 which included people diagnosed to the end of 
2010 [7]. People were excluded if information on sex 
or date of HIV diagnosis was missing, or where there 
was evidence of an earlier HIV diagnosis (CD4 count, 
AIDS diagnosis, or having started antiretroviral therapy 
Figure 1
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(ART)) more than one month before first clinic visit, 
as were people from Argentinean centres in EuroSIDA 
[21]. People from the seroconverter cohorts in COHERE 
were also excluded, as in our previous work [7]. By 
definition, such people are diagnosed soon after HIV 
infection, even if they have a low CD4 count at HIV-1 
diagnosis.
Definitions of late presentation
LP was defined as an individual diagnosed with HIV 
with a CD4 count below 350/mm3 or an AIDS-defining 
event regardless of the CD4 count, in the six months 
following HIV diagnosis. LP with advanced disease was 
defined as an individual diagnosed with HIV with a 
CD4 count below 200/mm3 or an AIDS defining event, 
regardless of CD4 cell count, in the six months follow-
ing HIV diagnosis. LP with very advanced disease was 
defined as an individual diagnosed with HIV with a CD4 
count below 50/mm3 or an AIDS defining event, regard-
less of CD4 cell count, in the six months following 
HIV diagnosis. The proportion presenting with AIDS, 
regardless of the CD4 count at which it occurred, was 
also presented. Delayed entry into care was defined 
as more than three months between HIV diagnosis 
and first clinic visit, in those where both dates were 
recorded. All people were required to have at least 
one CD4 count measured in the six months following 
diagnosis.
Statistical methods
Baseline characteristics of late presenters were com-
pared with those of non-late presenters and logistic 
regression was used to identify factors associated 
with late presentation and late presentation with 
advanced disease. Factors investigated were age, HIV 
exposure group (men who have sex with men (MSM), 
heterosexual men, heterosexual female, male PWID, 
female PWID, other (including patients with unknown 
HIV exposure group)), continent of origin (Europe, 
Africa, other (including patients from Central/Southern 
Figure 2








2010 (n=10,766) 2011 (n=10,054) 2012 (n=6,259) 2013 (n=3,375)
Late presentation Late presentation with advanced disease
Late presentation with very advanced disease AIDS






































COHERE: Collaboration of Observational HIV Epidemiological Research Europe.
Late presentation: diagnosed with HIV with a CD4 count below 350/mm3 or an AIDS defining event regardless of the CD4 count, in the six 
months following HIV diagnosis.
Late presentation with advanced disease: diagnosed with HIV with a CD4 count below 200/mm3 or an AIDS defining event, regardless of CD4 
cell count, in the six months following HIV diagnosis.
Late presentation with very advanced disease: diagnosed with HIV with a CD4 count below 50/mm3 or an AIDS defining event, regardless of 
CD4 cell count, in the six months following HIV diagnosis
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America and Asia), unknown), region of HIV diagnosis 
in Europe, based on the cohort location and defined 
similarly to the EuroSIDA study [22] (Table 1), calendar 
year of diagnosis, and delayed entry into care.
A priori, we were interested in comparing changes over 
time within region of HIV diagnosis in Europe and HIV 
exposure groups. Simple descriptive data were used 
to present the proportions of LP, advanced LP, very 
advanced LP and presentation with AIDS by country; 
countries were grouped into regions and anonymised, 
those countries with less than 50 people included 
were combined. Linear regression was used to assess 
change over time in CD4 counts overall and among 
LP, and Cox proportional hazards models were used 
to compare the risk of development of a new clinical 
event i.e. a new AIDS defining illness occurring more 
than one month after the first if the person had AIDS 
within six months of baseline or death), whether this 
has changed over time, and at a similar rate for LP and 
non-LP.
Descriptive analyses were used to investigate whether 
someone classified as a LP based on a CD4 count > 350/
mm3 (but no AIDS diagnosis) would not be a LP if the 
next CD4 count was used (misclassification). This anal-
ysis was limited to the small subset with CD4 counts 
measured after HIV diagnosis and before starting ART. 
Logistic regression was used to determine whether 
potential misclassification of people as LP had changed 
over time, after adjusting for age, HIV exposure group, 
region of origin, region of HIV diagnosis in Europe, 
Figure 3
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 0.99 (0.96–1.03) 0.99 (0.93–1.05) 1.04 (0.98–1.09) 1.16 (1.03–1.31) 1.10 (1.02–1.17)
0.98 (0.95 – 1.01) 0.97 (0.91 – 1.03) 0.99 (0.93 – 1.05) 1.16 (1.02 – 1.32) 1.08 (1.00 – 1.16)
Odds of late presentation: per year later of presentation.
Univariate
Multivariatea
COHERE: Collaboration of Observational HIV Epidemiological Research Europe; F: female; Het: heterosexual; LP: late presentation; M: male; 
MSM: men who have sex with men; PWID: people who inject drugs.
aAdjusted for age, region of care in Europe, continent of origin, delayed access to care.
Late presentation: diagnosed with HIV with a CD4 count below 350/mm3 or an AIDS defining event regardless of the CD4 count, in the six 
months following HIV diagnosis.
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calendar year of diagnosis, delayed entry into care, and 
CD4 count and HIV viral load at HIV diagnosis.
All analyses were performed using Statistical Analysis 
Software Version 9.3 (Statistical Analysis Software).
Results
Of 37,859 people with a HIV-1 test after 1 January 2010, 
4,197 were excluded because they were aged < 16, from 
seroconverter cohorts, or where there was evidence 
that the person had started ART, had a CD4 count or 
an AIDS diagnosis more than 28 days before the first 
reported HIV-1 test. A further 3,208 of 33,662 (9.5%) 
were excluded due to missing CD4 counts, 9.6% from 
south Europe and 8.6%, 9.8% and 13.5% from central, 
northern and eastern Europe respectively. Compared 
with the 30,454 included, those excluded due to miss-
ing CD4 counts were more likely to be PWID, from other 
(including unknown) HIV exposure groups, and to be in 
care in northern, central or eastern Europe compared 
with southern Europe (Figure 1). Older people were less 
likely to be excluded, as were those with a more recent 
test for HIV.
Late presentation and changes over time
Table 2 summarises the characteristics of the 30,454 
people included, stratified by LP status; 14,586 
(47.9%) were LP, ranging from > 60% of heterosexual 
men or people originating from Africa to ca 39% MSM 
and female PWID.
Figure 4
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1.04 (1.00–1.07) 1.01 (0.97–1.05) 0.93 (0.89–0.97) 1.12 (0.97–1.31)
1.02 (0.99–1.06) 1.04 (1.00–1.09) 0.89 (0.85–0.94) 1.05 (0.90–1.23)
Odds of late presentation: per year later of presentation.
Univariate
Multivariateb
2010 (n=10,766) 2011 (n=10,054) 2012 (n=6,259) 2013 (n=3,375)
COHERE: Collaboration of Observational HIV Epidemiological Research Europe; LP: late presentation.
aAdjusted for age, HIV exposure group, region of origin, delayed access to care.
b No data available for 2013.
Late presentation: diagnosed with HIV with a CD4 count below 350/mm3 or an AIDS defining event regardless of the CD4 count, in the six 
months following HIV diagnosis.
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Among people in whom both first visit and HIV test 
date were known, 1,247/27,818 (4.5%) had delayed 
entry into care. Figure 2 shows the annual proportion 
of people with LP, LP with advanced or very advanced 
disease, and with an AIDS diagnosis, regardless of the 
CD4 count at presentation.
In 2010 4,775/10,766 (47.5%) were LP, compared with 
1,642/3,375 (48.7%) in 2013 or later (p = 0.63). The 
proportion of people with LP, advanced disease, very 
advanced disease, or AIDS did not change significantly 
over time (p = 0.63, 0.090, 0.16, and 0.075 respec-
tively). The proportion of those presenting who would 
be eligible for starting cART with a CD4 count of <500/
mm3 was 69.0% in 2010, 68.8% in 2011, 68.3% in 2012 
and 69.0 in 2013 or later (p = 0.77).
In multivariate analyses, there was no evidence of a 
change over time in LP (adjusted odds ratio (aOR) 0.99/
year later; 95% confidence interval (CI): 0.97–1.02; 
p = 0.60), or in LP with advanced disease (aOR 0.99/
year later; 95% CI: 0.97–1.02; p = 0.65). This finding 
was consistent across a wide range of sensitivity anal-
yses, such as including those with AIDS but without a 
CD4 count measured as LP, including deaths within the 
first six months as LP, when the window required for 
a CD4 count after HIV diagnosis to three months, and 
defining LP as a CD4 count < 350/mm3 or an AIDS diag-
nosis within three months of HIV diagnosis. There was 
some evidence that presentation with very advanced 
disease had decreased over time by 3% per year later 
(aOR 0.97/year later; 95% CI: 0.93–1.00; p = 0.035), 
and that LP based on an AIDS diagnosis alone, regard-
less of the CD4 count at which it was diagnosed, had 
decreased by 7% per year (aOR 0.93; 95% CI: 0.89–
0.96; p = 0.0001).
Changes in CD4 count at presentation
The median CD4 count at presentation was 368/mm3 
(interquartile range (IQR) 193–555/mm3). There was no 
evidence of a change over time in the median CD4 count 
at presentation (p=0.70), suggesting that overall, the 
level of immunodeficiency at which HIV was diagnosed 
has not changed over time (adjusted change/year 1.2/
mm3; 95% CI: -0.8 to 3.3/mm3; p = 0.89). Similar results 
were seen in an analysis limited to LP (adjusted change/
year -1.1/mm3; 95% CI: -3.1 to 0.8/mm3, p = 0.31), dem-
onstrating that LP are diagnosed with HIV at a similar 
level of immunodeficiency between 2010 and 2013.
Of 14,586 LP, 3,984 (27.3%) did not have AIDS as part 
of the LP definition and had at least one CD4 count 
during follow-up before starting ART. Among these, for 
1,067 (26.8%) the next CD4 count was > 350/mm3, sug-
gesting they may not be LP or they may be seroconvert-
ers; this proportion was highest for MSM (698/2,154; 
32.4%), and was ca 20% in all other HIV exposure 
groups (p < 0.0001). There was some evidence that the 
proportion that may be incorrectly classified as LP had 
increased over time (aOR 1.14/year later; 95% CI: 1.04–
1.28; p = 0.0050). This proportion of potentially misclas-
sified LP was lower using a confirmed CD4 count > 350/
mm3 (317/1,279 (24.8%) with more than two CD4 counts 
after HIV diagnosis and before ART started).
Changes in late presentation in HIV exposure 
groups and regions of Europe
Figure 3 summarises the change over time in LP among 
HIV exposure groups. Male and female PWID were com-
bined due to smaller numbers as were men and women 
belonging to the ‘other’ risk groups. There was strong 
evidence to suggest that the rate of change in LP dif-
fered between HIV exposure groups (p < 0.0001, test 
for interaction). After adjustment, there was no change 
over time in LP among MSM, or male or female het-
erosexuals, but there was a significant increase in LP 
among PWID (both men and women combined) (aOR 
1.16/year later; 95% CI: 1.02–1.32; p = 0.024) and in the 
other exposure groups (aOR 1.08/year later; 95% CI: 
1.00– 1.16, p = 0.040).
LP was most common in central Europe (4,791/9,625, 
49.8%), followed by northern (5,704/11,692; 48.8%), 
southern (3,550/7,760; 45.8%) and eastern Europe 
(541/1,377; 38.3%; p<0.0001). There were consider-
able differences in LP in countries within regions of 
care in Europe (Table 3), particularly within eastern 
Europe. Figure 4 presents similar data to Table 3, strati-
fied by region of care in Europe, with evidence to sug-
gest the rate of change in LP differed between regions 
(p < 0.0001; test for interaction). There was a marginally 
significant increase in LP over time in central Europe 
Region in Europe Countries included
Northern Denmark, Finland, Ireland, the Netherlands, Norway, Sweden, United Kingdom
Southern Greece, Israel, Italy, Portugal, Spain
Central Austria, Belgium, France, Germany, Luxemburg, Switzerland
Eastern Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Russia, Serbia, Slovakia, Slovenia, Ukraine
Table 1
Geographical categorisation of European countries to regions, COHERE study, 2010–2013a
COHERE: Collaboration of Observational HIV Epidemiological Research Europe.
a Defined similarly to the EuroSIDA study [22].
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(aOR 1.04/year later; 95% CI: 1.00–1.09, p = 0.084), 
and a significant decrease in LP over time in northern 
Europe (aOR 0.89; 95% CI: 0.85–0.94; p < 0.0001).
Clinical disease progression
During 39,790 person-years of follow-up (PYFU) 886 
(2.9%) people developed a new AIDS defining illness 
or died, giving an incidence of clinical progression of 
22.3/1,000 PYFU (95% CI: 20.8–23.7). A total of 409 
disease progression events were death, 486 were a 
new AIDS event, and nine patients had both types of 
events on the same date. There were no differences in 
the proportion of events that were attributable to AIDS 
(63/125 (50.4%) vs 423/761 (55.6%); p=0.28), deaths 
(63/125 (50.4%) vs 346/761 (45.5%); p=0.31), or in the 
specific AIDS events diagnosed (p=0.053) comparing 
LP and non-LP. The incidence of clinical progression 
was 6.5-fold higher among LP (761 events, 39.6/1,000 
PYFU; 95% CI: 36.8–42.4) compared with non-LP (125 
events, 6.1/1,000 PYFU; 95% CI: 5.0–7.1).
There was no evidence of any change over time in the 
risk of developing a new AIDS event or death within the 
first six months of presentation or after this time (Table 
4). For example, after adjustment, there was no change 
over time in the risk of developing a new clinical event 
per year later of presentation after six months of fol-
low-up (adjusted hazard ratio (aHR) 1.04/year later; 
95% CI: 0.91–1.19, p = 0.40). There was no evidence 
that this relationship differed in LP vs non-LP (test 
for interaction > 0.2), and the results are also shown 
in Table 4. These findings were also consistent for 
Patients’ characteristics
All Late presenters
N Percentage (%)a N Percentage of late presenters (%)b
All 30,454 100 14,586 47.9
Delayed entry to 
carec
No 26,751 95.5 12,818 47.9
Yes 1,247 4.5 494 39.6
HIV exposure 
group
MSM 15,371 50.5 5,993 39.0
Heterosexual men 4,826 15.8 3,011 62.4
Heterosexual females 5,487 18.0 2,864 52.2
PWID (male) 843 2.8 481 57.1
PWID (female) 321 1.1 126 39.3
Male other 2,551 8.8 1,495 58.6
Female other 1,055 3.5 616 58.4
Region of 
care in Europe
Southern 11,692 38.4 5,704 48.8
Central 9,625 31.6 4,791 49.8
Northern 7,760 25.5 3,550 45.8
Eastern 1,377 4.5 541 38.3
Continent of origin
Europe 20,701 68.0 9,495 45.9
Africa 2,651 8.7 1,696 64.0
Other 2,685 8.8 1,428 53.2
Unknown 4,417 14.5 1,967 44.5
Median IQR Median IQR 
Age Years 36 29–45 39 31–48
CD4 /mm3 368 193–555 184 73–276
Baselined Month/year 6/2011 9/2010–4/2012 6/2011 9/2010–4/2012
Table 2
Characteristics of included patients, COHERE study, 2010–2013 (n=30,454)
COHERE: Collaboration of Observational HIV Epidemiological Research Europe; IQR: interquartile range; MSM: men who have sex with men; 
PWID: people who inject drugs.
a% represents percentage of total; for example, 15,371/30,454 (50.5%) of the population included were MSM.
b % represents the percentage of late presenters; for example, 5,993/15,371 (39.0%) of MSM were late presenters.
c Delayed entry into care was defined as more than three months between HIV diagnosis and first visit to clinic, in people with both dates 
recorded (n = 27,998).
d Baseline was defined as the earliest of HIV test, first study visit or cohort enrolment.
Late presentation: diagnosed with HIV with a CD4 count below 350/mm3 or an AIDS defining event regardless of the CD4 count, in the six 
months following HIV-diagnosis [8].
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different HIV exposure categories and across regions 
of care in Europe and when using death alone as the 
clinical endpoint.
Discussion
This study, which included more than 30,000 people 
from across 34 European countries, demonstrated no 
overall change in the proportion of LP across Europe 
since 2010. LP increased significantly in PWID as pre-
sumed HIV exposure. This lack of improvement in diag-
nosing HIV earlier was consistent across a wide range 
of analyses; there was no change over time in LP with 
advanced disease, in the average CD4 count at pres-
entation, or in progression to a new AIDS event/death.
The proportion of LP decreased significantly across 
Europe between 2000 and 2010 [7], but despite numer-
ous interventions and initiatives in recent years to 
optimise testing for HIV, we found no overall change 
between 2010 and 2013 in the proportion of LP across 
Europe. LP is impacted by the underlying incidence of 
HIV which itself is difficult to estimate [5]. If HIV inci-
dence increases and HIV testing does not change, the 
proportion of LP will decline as more are diagnosed 
early. Conversely, if incidence is declining and HIV test-
ing does not change, the proportion of LP increases. 
Assuming the overall incidence of HIV is not decreasing 
in Europe, as there appears to have been no decline 
in HIV diagnoses per 100,000 population over the last 
decade [4], our findings of no decrease in LP overall 
suggests there are areas for further interventions for 
reducing LP on a European level. A more detailed anal-
ysis by region showed a small decrease over time in 
LP from northern Europe, but not from other regions. 
Combining countries into these regions was decided 
a priori and used the stratification previously used by 
EuroSIDA [23]. Such a broad grouping may not be ideal 
for a number of reasons, including history, politics 
and economy and the rates of LP within regions varied 
considerably, reflecting this heterogeneity. HIV surveil-
lance in Europe for the European Union (EU)/European 





of care in 
Europe 
Country N % 95% CI % 95% CI % 95% CI % 95% CI 
Southern a 40 55.0 39.6–70.4 27.5 13.7–41.3 7.5 0.0–15.7 2.5 0.0–7.3
Southern 1 1,097 45.9 43.0–48.9 25.9 23.3–28.5 12.5 10.5–14.4 8.1 6.5–9.7
Southern 2 4,782 53.9 52.5–55.3 33.9 32.6–35.2 17.1 16.1–18.2 9.6 8.7–10.4
Southern 3 5,773 45.0 43.8–46.3 25.8 24.7–26.9 14.3 13.4–15.2 11.0 10.2–11.8
Central a 19 31.6 10.7–52.5 15.8 0.0–32.2 10.5 0.0–24.3 5.3 0.0–15.3
Central 1 568 43.7 39.6–47.7 24.6 21.1–28.2 13.4 10.6–16.2 11.3 8.7–13.9
Central 2 778 47.6 44.0–51.1 27.9 24.7–31.0 17.4 14.7–20.0 14.1 11.7–16.6
Central 3 810 54.9 51.5–58.4 30.9 27.7–34.0 15.1 12.6–17.5 11.6 9.4–13.8
Central 4 2,675 56.2 54.3–58.1 37.2 35.3–39.0 24.6 23.0–26.2 20.0 18.5–21.6
Central 5 4,775 46.5 45.1–47.9 25.1 23.8–26.3 13.5 12.5–14.5 10.5 9.6–11.3
Northern a 21 47.6 26.3–69.0 33.3 13.2–53.5 19.0 0.0–35.8 14.3 0.0–29.3
Northern 1 600 52.7 48.7–56.7 33.7 29.9–37.4 19.3 16.2–22.5 13.2 10.5–15.9
Northern 2 3,419 44.7 43.1–46.4 24.2 22.7–25.6 11.7 10.7–12.8 7.6 6.7–8.5
Northern 3 3,720 45.5 43.9–47.1 26.7 25.3–28.1 17.4 16.2–18.7 14.2 13.1–15.4
Eastern 1 74 63.5 52.5–74.5 18.9 10.0–27.8 8.1 1.9–14.3 6.8 1.0–12.5
Eastern 2 84 50.0 39.3–60.7 26.2 16.8–35.6 19.0 10.7–27.4 19.0 10.7–27.4
Eastern a 98 58.2 48.4–67.9 39.8 30.1–49.5 24.5 16.0–33.0 19.4 11.6–27.2
Eastern 3 1,121 35.2 32.4–38.0 12.1 10.2–14.0 1.4 0.7–2.1 0.7 0.2–1.2
Table 3
Late presentation, late presentation with advanced disease, late presentation with very advanced disease and presentation 
with an AIDS defining event at any CD4 count stratified by country, COHERE study, 2010–2013
COHERE: Collaboration of Observational HIV Epidemiological Research Europe.
a Represents > 1 country within specific regions where countries with < 50 people have been combined.
Late presentation: diagnosed with HIV with a CD4 count below 350/mm3 or an AIDS defining event regardless of the CD4 count, in the six 
months following HIV diagnosis.
Late presentation with advanced disease: diagnosed with HIV with a CD4 count below 200/mm3 or an AIDS defining event, regardless of CD4 
cell count, in the six months following HIV diagnosis.
Late presentation with very advanced disease: diagnosed with HIV with a CD4 count below 50/mm3 or an AIDS defining event, regardless of 
CD4 cell count, in the six months following HIV diagnosis.
AIDS: presentation with AIDS regardless of CD4 count.
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Centre for Disease Prevention and Control (ECDC) in 
collaboration with the WHO Regional Office for Europe 
and the ECDC report displays LP in central-east and 
eastern Europe separately [4]; in this study, they were 
combined due to small numbers from the central-east 
region. Further, combining southern, central and north-
ern Europe into one region in our study to compare to 
ECDC data may hide important findings within these 
regions. Despite these differences in classification, the 
proportion with LP in this study was very similar to that 
recently reported by the ECDC [4], who reported eight 
countries with > 50% as LP, including Greece and Italy, 
both of which contributed significant numbers to our 
analyses.
Possible action points for increasing HIV awareness 
and HIV testing, and therefore minimising LP include 
a combination of both community-based and provider-
initiated models for HIV testing, removal of stigmatisa-
tion, as well as working towards acceptance of verbal 
informed consent for testing [16,18,24,25]. Community-
based testing should be a priority, as should targeting 
key populations.
Previous analyses from COHERE showed an increase 
in LP among PWID from southern and eastern Europe 
[7], a trend that continued in these analyses. It is worth 
noting again that these data are difficult to interpret; 
the number of new diagnoses of HIV is declining in 
PWID in Europe [4] and if HIV testing is stable this 
could lead to an increase in the proportion of PIWD 
presenting late. Although PWID account for a compara-
tively small proportion of new HIV infections in west-
ern Europe, this route of transmission is more common 
in eastern Europe [4,7], and issues continue to exist 
around needle exchange, opiate substitution therapy, 
as well as access to ART and retention in care once HIV 
has been diagnosed [26,27]. Recent data suggest that 
those in prison and migrants were among those least 
likely to be targeted for HIV testing; with challenges 
being providing HIV services and support, although the 
ECDC-funded report by Deblonde et al. acknowledges 
excellence in some countries [28]. Further, PWID are 
more likely to face greater barriers to accessing health-
care and to belong to lower socioeconomic groups and 
have lower levels of education, all factors known to be 
associated with poorer medical outcomes [29,30]. Thus 
while there is evidence for barriers for PWID to access 
care and be retained in care, there is much less evi-
dence that HIV is not diagnosed, or that diagnosis of 
HIV or access to care is even worsening.
We found a small decline in the proportion of LP with 
very advanced disease or in the proportion presenting 
with AIDS over time. The fact that the CD4 count at pres-
entation has remained stable over time may suggest 
that health systems are better able to recognise and 
capture people with symptomatic HIV disease occurring 
at higher CD4 counts and that asymptomatic patients 
are not routinely diagnosed with HIV, especially in 
groups at low risk of HIV infection. Evidence from other 
studies concerning changes over time in CD4 count at 
presentation in recent times have shown mixed results 
[31-34]; some have limited data from 2011 and others 
have not been able to adjust for confounding variables. 
Other studies have described a decrease in the propor-
tion presenting with AIDS [35,36], although the extent 
to which this is due to the under-reporting of AIDS is 
unknown.
We found no evidence of a change over time in short-
term clinical progression (within six months) or after 
that time in all people or in LP and non-LP considered 
separately, in different regions of Europe or HIV expo-
sure categories, although median follow-up was limited 
by only including people diagnosed with HIV-1 since 
2010. The greatest risk in clinical progression for LP 
has been observed in the years immediately following 
LP [7,10,37,38], and in this study, LP had approximately 
a six-fold higher incidence of clinical progression. A 
lack of change in clinical outcomes in LP over calendar 
time suggests that, once people have accessed care, 
treatment and outcomes are uniform across a variety 
of settings. Given the poor outcomes after LP, work is 
needed to reduce the proportion of those presenting 
In first six months after presentation More than six months after presentation
HR  95% CI P HR 95% CI p
All
Univariate 1.02 0.92–1.11 0.83 1.01 0.89–1.15 0.87
Multivariate a 0.98 0.89–1.08 0.73 1.04 0.91–1.19 0.40
Non-LP
Univariate 0.99 0.64–4.53 0.95 1.04 0.77–1.40 0.79
Multivariate a 0.92 0.59–1.45 0.73 0.98 0.89–1.09 0.72
LP
Univariate 1.01 0.92–1.12 0.83 1.00 0.87–1.16 0.98
Multivariate a 1.06 0.78–1.44 0.71 1.05 0.90–1.22 0.54
Table 4
Relative hazard of a new AIDS defining event or death following HIV diagnosis per year later of presentation, COHERE 
study, 2010–2013
CI: confidence interval; COHERE: Collaboration of Observational HIV Epidemiological Research Europe; HR: hazard ratio; LP: late presentation.
a Multivariate models were adjusted for age, HIV exposure group, region of care in Europe, continent of origin, and whether an AIDS diagnosis 
was present at baseline. The model in all patients adjusts additionally for late presentation.
All HR are per year later of presenting for care.
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late to reduce morbidity and mortality associated with 
HIV, as well as to reduce the financial impact on health 
systems and onward transmission of HIV [9-11].
It is possible that some people presenting with symp-
tomatic seroconversion for HIV are misclassified as 
LP due to the transient drop in CD4 count occurring at 
this time [39]. Misclassification of LP may be highest 
in MSM [40]. In our study, there was a small subset 
with CD4 counts after HIV diagnosis but before starting 
antiretroviral therapy. Approximately 20% did not have 
a CD4 count of < 350/mm3 at the next CD4 count, and 
this proportion was highest for MSM. This proportion 
was similar when using a confirmed CD4 count of > 350/
mm3, suggesting this is not largely due to laboratory 
variation, although it is worth noting that only a small 
subset of people had one or two CD4 counts after HIV 
diagnosis and before starting ART. In addition, only 
5% had a CD4 count >500/mm3 at the second measure-
ment, which is higher than the currently recommended 
threshold for initiation of antiretroviral therapy [12]. 
In addition, we found no changes over time in the 
proportion of LP, presentation with advanced or very 
advanced disease, suggesting that an increasing pro-
portion of primary HIV infections is unlikely to explain 
the lack of change in LP in recent years.
There are a number of limitations which should be con-
sidered. We are likely underestimating LP as people 
who do not survive long enough to have a CD4 count 
measured were excluded [41]. Our data suggest this 
was more likely in PWID, other HIV exposure groups, 
those under care in northern and eastern Europe, and 
affected ca 10% of those in the COHERE cohorts. This 
is considerably lower than reported by surveillance 
studies [42], highlighting that cohort studies such as 
COHERE can supplement information available from 
the WHO or ECDC. Furthermore, cohorts participating 
in COHERE tend to be receiving healthcare at centres 
of excellence and clinic-based cohorts rather than non-
clinic outpatient settings, where LP may be higher. 
We excluded seroconverter cohorts participating in 
COHERE as in our previous work, where inclusion of 
these cohorts did not alter our findings [7]. Even in 
a collaboration as large as COHERE we were not able 
to consider LP for male and female PWID separately, 
although it is worth noting that there was no statisti-
cally significant rise in LP in any one region, suggest-
ing that the problem of LP in IDUs is not limited to one 
region of Europe, but a potential problem on a wider 
scale.
In conclusion, LP across Europe account for almost 
50% of HIV diagnoses with no evidence of a change 
since 2010. Increased HIV testing, with a focus on vul-
nerable groups, will reduce the harm for the individual 
and it may as well reduce onward transmission. Earlier 
diagnosis for HIV is an important component of achiev-
ing the UNAIDS target of ending the AIDS epidemic by 
2030 [1].
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